NoName_910

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: NoName_910
• 英文别名: 2-(1-methylpiperidin-1-ium-1-yl)acetic acid
• 化学式: C8H16NO2+
• 分子量: 158.22
• InChiKey: CRXFBHQGNFQOHL-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Poly(ADP-ribose) polymerase 1 inhibitors structurally unrelated to NAD
  申请人：Institute for Cancer Research

  公开号：US10550108B2

  公开（公告）日：2020-02-04

  Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

  本研究提供了与 NAD 无关的、针对 PARP1-组蛋白 H4 相互作用的化合物以及这些化合物的组合物，并提供了使用这些化合物特异性抑制聚（ADP-核糖）聚合酶 1（PARP-1）的方法。这些 PARP-1 抑制剂可用于治疗 PARP-1 活化或生物活性起作用的癌症，包括前列腺癌、乳腺癌、肾癌、卵巢癌、淋巴瘤、白血病和胶质母细胞瘤等。
• EP3200792A2
  申请人：——

  公开号：EP3200792A2

  公开（公告）日：2017-08-09
• Poly(ADP-Ribose) Polymerase 1 Inhibitors Structurally Unrelated to NAD
  申请人：Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center

  公开号：US20170283402A1

  公开（公告）日：2017-10-05

  Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
• [EN] NOVEL IONIC LIQUIDS<br/>[FR] NOUVEAUX LIQUIDES IONIQUES
  申请人：UNIV LEUVEN KATH

  公开号：WO2007147222A9

  公开（公告）日：2008-02-14

  [EN] The present invention provides for novel organic salts, more specifically ionic liquids and for methods for the preparation of such novel ionic liquids. The invention also provides for the use of the ionic liquids in chemistry applications, for example for the solubilization of metal oxides, hydroxides and salts, for the deposition of metals or for extraction procedures, among others. The invention furthermore provides for a method for the solubilization of metal oxides and metal salts, for the deposition of metals and for extraction procedures, this by using the novel ionic liquids. The present invention furthermore provides for materials obtained by the methods hereof.
  [FR] La présente invention concerne de nouveaux sels organiques, plus spécifiquement des liquides ioniques et les procédés de préparation de tels nouveaux liquides ioniques. L'invention concerne également l'utilisation des liquides ioniques dans des applications en chimie, par exemple, dans la solubilisation d'oxydes, d'hydroxydes et de sels métalliques, dans le dépôt de métaux ou dans des procédures d'extraction, entre autres. L'invention concerne, en outre, un procédé de solubilisation d'oxydes métalliques et de sels métalliques, de dépôt de métaux, le procédé s'appliquant aussi à des procédures d'extraction, ceci en utilisant les nouveaux liquides ioniques. La présente invention concerne, en outre, des matériaux obtenus par les présents procédés.
• [EN] POLY (ADP-RIBOSE) POLYMERASE 1 INHIBITORS STRUCTURALLY UNRELATED TO NAD<br/>[FR] INHIBITEURS DE POLY(ADP-RIBOSE) POLYMÉRASE 1 STRUCTURELLEMENT NON APPARENTÉS À NAD
  申请人：INST CANCER RES D B A THE RES INST OF FOX CHASE CANCER CT

  公开号：WO2016054237A2

  公开（公告）日：2016-04-07

  Compounds that are not related to NAD, and which target PARPl-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.